Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Pharmacists want full script powers

GPs will have to wait for clarification on their use of cox-2 inhibitors after the European Medicines Agency stalled from giving advice.

The EMEA announced its review of cox-2s in Oct-

ober, following the withdrawal of rofecoxib after a long-

term study showed increased risk of heart attack and stroke.

Its expert committee this week requested more analysis of data from two new long-term trials with celecoxib.

One showed an increased risk of heart attack and stroke after taking the drug but the other showed no increased risk.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say